FGF21 and metabolic dysfunction-associated steatotic liver disease: Furthermore, sweroside improves nonalcoholic fatty liver disease in mice by modulating the expression of the Cd36 and Fgf21 genes, thereby impacting lipid metabolism and the inflammatory response (Yang et al., 2020).